variant,gene_symbol,summary,clinical_importance,evidence,impact,frequency,category,inheritance,zygosity,PMIDs,dbSNP_ID,penetrance_score,build_37_chromosome,build_37_position,build_37_variant_allele,getev_report_url
APOE-C130R,APOE,"This is generally known as the ApoE4 allele of ApoE and is associated with increased risk of Alzheimer's. 20-25% of individuals are heterozygous for this variant, and 1-2% are homozygous. Data from Khachaturian et al. suggests an average 7% of all individuals developed Alzheimer's by the age of 80; when this is split by ApoE4 status: 10% of ApoE4 heterozygotes (3% increased attributable risk), 40% of ApoE4 homozygotes (33% increased attributable risk), and 5% of non-carriers (2% decreased attributable risk). Notably, their model suggests 70-75% of people would eventually develop Alzheimer's by the age of 100 regardless of ApoE4 genotype (and 25-30% are resistant, regardless of genotype), but that ApoE4 variants shift the disease onset to occur significantly earlier (4 years earlier for heterozygous carriers, 13 years for homozygotes).",High,Well-established,Pathogenic,0.14,Mental and behavioral;Nervous system,Complex/Other,Homozygous,9343467;11950276;15123497;17428983,rs429358,4,chr19,45411941,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
COL4A1-Q1334H,COL4A1,"This common variant has been associated with arterial stiffness and, in Japanese, a small increased risk of myocardial infarction (MI, a.k.a. heart attack). This last observation supported a dominant effect for this variant and, assuming a lifetime risk of 15% for MI, we estimate carriers have an additional risk of 0.5-3%.",Low,Likely,Pathogenic,0.32,Heart and circulatory,Dominant,Heterozygous,10334796;18077766;20031579,rs3742207,2,chr13,110818598,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
MBL2-G54D,MBL2,"This variant is associated with mannose binding protein deficiency which leads to impaired complement system immune response to mannose-rich pathogens. Patients homozygous for this allele or compound heterozygous are likely to have increased susceptibility to infection, but Hellemann et al. report heterosis for intensive care outcomes in heterozygous subjects. The wild-type version of this gene is known as variant allele A, while this is called variant allele B. See R52C (variant D) and G57E (variant C).",Low,Likely,Pathogenic,0.1,Immune system,Recessive,Heterozygous,7564730;10199352;17872904,rs1800450,3,chr10,54531235,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
AMPD1-Q12X,AMPD1,"Causes Adenosine Deaminase Deficiency in a recessive manner. Most of the time individuals do not report symptoms, but when symptoms do exist they to be post-exercise symptoms of muscle weakness, muscle pain, and getting tired more quickly.",Low,Likely,Pathogenic,0.093,"Metabolism;Muscular, skeletal, and connective tissue",Recessive,Heterozygous,1631143,rs17602729,4,chr1,115236057,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
MTRR-I49M,MTRR,"This common variant (HapMap allele frequency of 31.3%) in a protein involved in folate (B9) and cobalamin (B12) metabolism and is often reported as ""MTRR I22M"" (an alternative transcript position). Mothers homozygous for this variant are associated with having around a increased chance of a child with Down syndrome (risk of 0.4%, average risk in population is 0.25%). Notably, age plays a far larger role in the rate of Down syndrome (risk is 4.5% for a mother 45-years-of-age), and it is unknown how this variant may combine with the effect of age. There are conflicting reports associating this variant with incidence of neural tube defects, possibly when combined with MTHFR A222V.",Low,Likely,Pathogenic,0.45,Anatomical and congenital;Metabolism;Nervous system,Recessive,Heterozygous,10444342;10930360;11807890;12375236;15060097;15979034;17024475,rs1801394,1,chr5,7870973,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
TGFB1-R25P,TGFB1,"This variant in a growth factor gene is associated with variation in TGFB1 levels; this has been associated with various pathogenic and some protective effects, including: more hepatic fibrosis progression in hep C patients, lower risk of cleft palate, anticorrelation with longevity, higher risk of myocardial infarction and lower risk of hypertension.",Low,Uncertain,Pathogenic,0.049,Anatomical and congenital;Heart and circulatory,Complex/Other,Heterozygous,8901839;14596813;15212689;15569360,rs1800471,2,chr19,41858876,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
H6PD-R453Q,H6PD,"This common variant may have a small pathogenic effect by contributing to cortisone reductase deficiency (a rare abnormality) when homozygous and combined with a serious pathogenic variant. The same authors have tested and ruled out a contribution to polycystic ovary syndrome (similar phenotype, more common disease).",Low,Uncertain,Pathogenic,0.31,Genital and urinary;Metabolism,Recessive,Heterozygous,12858176;15827106;16817821,rs6688832,1,chr1,9323910,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
ERCC6-R1213G,ERCC6,"When homozygous, this variant may cause Cockayne Syndrome, which is a severe autosomal-recessive disorder characterized by abnormal early growth and development, abnormal sensitivity to sunlight, and premature aging. Cockayne Syndrome Type I and Type II lead to death in early childhood. Several other variants in the ERCC6 gene are linked to Cockayne Syndrome. This variant may also be linked to age-related macular degeneration like other ERCC6 variants, and has been linked to colorectal cancer in one study. ",Low,Uncertain,Pathogenic,0.2,Anatomical and congenital;Cancer;Hearing and vision,Recessive,Heterozygous,,rs2228527,0,chr10,50678369,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
SP110-L425S,SP110,"This variant is associated with a slightly increased risk of tuberculosis. It is unclear whether it is itself causal, or in linkage disequilibrium with some other causal variant that has a stronger effect.",Low,Uncertain,Pathogenic,0.86,Immune system,Unknown,Heterozygous,16803959,rs3948464,1,chr2,231050715,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
BRCA2-N372H,BRCA2,"This is a common variant of BRCA2 (HapMap allele frequency of 23%). The variant is weakly associated with an increased chance of breast cancer, and zygosity of the variant is associated with sex of children: male children are more likely to be homozygous for this variant, female children are more likely to be heterozygous.",Low,Uncertain,Pathogenic,0.24,Cancer,Recessive,Heterozygous,11062481;15235023,rs144848,2,chr13,32906729,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
TP53-P72R,TP53,"This is a common variant was first reported as a polymorphism. It has since had mixed associations with cancer: Storey et al. conclude a 7x *increased* risk of HPV cancer for homozygotes vs hets, but Jones et al. find a 1.98x *decreased* risk for colorectal cancer. This variant may have significant impact on particular cancers, but it is unclear what effect it has on the overall burden of cancer.",Low,Uncertain,Pathogenic,0.63,Cancer,Unknown,Homozygous,1975675;9607760;15355915;19837266;20615891;22184967,rs1042522,0,chr17,7579472,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
CYP2C9-R144C,CYP2C9,"This variant, also called CYP2C9*2, is a pharmacogenetic variant that modulates sensitivity for Warfarin (due to reduced metabolism). This variant is associated with Caucasians. The FDA has approved reduced recommended Warfarin dosage based on the presence of this variant.",Moderate,Well-established,Pharmacogenetic,0.097,Drug response;Metabolism,Unknown,Homozygous,8004131;15947090;17161452;17686967;19228618;19794411;19794412,rs1799853,3,chr10,96702047,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
TPMT-Y240C,TPMT,"Alone, this variant is known as TPMT*3C -- but often, especially in Caucasians, it is found together with another nonsynonymous variant (A154T) to produce the TPMT*3A variant. Both variants are associated with loss of thiopurine methyltransferase (TPMT) activity, although *3C is milder than *3A. Inability to metabolize thiopurine drugs can lead to severe adverse reactions. Heterozygotes may be advised to take a reduced dosage due to reduced metabolism of the drug.",Low,Well-established,Pharmacogenetic,0.046,Drug response;Metabolism,Complex/Other,Heterozygous,15228163;15298741;20154640;20354201,rs1142345,2,chr6,18130918,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
TPMT-A154T,TPMT,"Usually this variant is found in combination Y240C, forming the TPMT*3A variant. When alone, this variant produces the *3B variant. Both variants are associated with loss of thiopurine methyltransferase (TPMT) activity. Inability to metabolize thiopurine drugs can lead to severe adverse reactions. Heterozygotes may be advised to take a reduced dosage due to reduced metabolism of the drug.",Low,Likely,Pharmacogenetic,0.028,Drug response;Metabolism,Recessive,Heterozygous,15228163;15298741;20154640;20354201,rs1800460,2,chr6,18139228,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
ABCC6-R1268Q,ABCC6,This common polymorphism appears to not have a significant phenotypic impact. A few studies report weak but significant associations with plasma lipids (in Inuits) and thalidomide toxicity.,Low,Uncertain,Pharmacogenetic,0.22,Metabolism,Unknown,Heterozygous,10811882;10913334;11776382;20038957,rs2238472,1,chr16,16251599,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
FUT2-W154X,FUT2,"This recessive protective variant confers resistance to norovirus (which causes stomach flu). 20% of Caucasians and Africans are homozygous for this variant and are ""non-secretors"": they do not express ABO blood type antigens in their saliva or mucosal surfaces. Most strains of norovirus bind to these antigens in the gut, and so this non-secretor status confers almost total resistantance to most types of norovirus. There are notable exceptions, some strains of norovirus bind a different target and are equally infectious for secretors and non-secretors.",Moderate,Well-established,Protective,0.49,Blood;Immune system,Recessive,Heterozygous,7876235;12692541;19625485;20031047;22025362,rs601338,5,chr19,49206674,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
PRNP-M129V,PRNP,"This variant is associated with some protective effects for prion disease -- individuals homozygous for this variant are less susceptible to Creutzfeldt-Jakob, and Papua New Guinea individuals heterozygotes at this site are less susceptible to kuru.

",Low,Well-established,Protective,0.34,Other,Complex/Other,Heterozygous,18236005;19081515,rs1799990,0,chr20,4680251,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
CFH-V62I,CFH,"Associated with a decreased risk for age related macular degeneration (ARMD). Homozygotes for this have a 4-5% decreased attributable risk (3-4% vs. average 8% risk), heterozygotes have slightly lower than average risk (7%). Non-carriers have an increased risk (12-13%). ARMD impairs sharp vision as age progresses. While there is no cure, treatment can slow progression of the disease and environmental factors (smoking and obesity) contribute to higher risk.",Low,Likely,Protective,0.39,Hearing and vision;Metabolism,Complex/Other,Heterozygous,15870199,rs800292,2,chr1,196642233,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
NPC1-H215R,NPC1,"This variant is associated with a reduced risk of obesity, with an additive effect of -0.084 BMI per allele (an average of 0.54 pounds less, per allele, in a 5'6"" individual).





",Low,Likely,Protective,0.3,Metabolism,Complex/Other,Heterozygous,19151714;19174833;19910939,rs1805081,2,chr18,21140432,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
KCNJ11-K23E,KCNJ11,"This variant is associated with decreased risk of type 2 diabetes. It is unclear whether this variant has additive effects, or acts in a dominant or recessive manner. Assuming diabetes has a lifetime risk of 36%, we estimate a decreased risk of around 1-2% per copy of this variant.",Low,Likely,Protective,0.74,Metabolism,Unknown,Heterozygous,17463246;17463248;20054294,rs5219,2,chr11,17409572,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
IL7R-T244I,IL7R,"The reference genome variant for this allele has been associated with a slight increased risk of multiple sclerosis. Thus, this variant can be treated as a ""protective"" variant -- carriers of this variant are slightly less likely to have MS. Because the disease is rare and the effect of this variant is not very strong, the absolute decreased risk for carriers of this variant is less than .05% (less than 1 in 2000).",Low,Likely,Protective,0.21,Immune system;Nervous system,Unknown,Heterozygous,12825072;17660530;17660816;17660817;21161391,rs6897932,0,chr5,35874575,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
MTR-D919G,MTR,"This variant was weakly associated with a protective effect vs. colorectal cancer, but only in individuals with low alcohol consumption.


",Low,Uncertain,Protective,0.22,Cancer,Complex/Other,Heterozygous,10498402;14744749;17417062;17855192,rs1805087,1,chr1,237048500,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
ARSA-N350S,ARSA,This common variant (HapMap 24.1% allele frequency) causes a loss of a glycosylation site (affecting the size of the protein when studied with gel electrophoresis) but does not affect enzyme activity or stability.,Low,Well-established,Benign,0.18,Other,Unknown,Heterozygous,2574462,rs2071421,,chr22,51064416,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
NEFL-S472Shift,NEFL,"Although a frameshift in this gene would be predicted to cause Charcot-Marie Neuropathy, this particular position appears to reflect a single base insertion error/mutation in the reference genome (in other words, normal individuals are always homozygous for a deletion at this position relative to reference). See chr8:24,811,060-24,811,080 annotations on UCSC.",Low,Likely,Benign,,Nervous system,Unknown,Homozygous,,rs11340767,,,,,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
PMS2-P470S,PMS2,"Benign, common variant.",Low,Likely,Benign,0.37,Other,Unknown,Heterozygous,15256438,rs1805321,,chr7,6026988,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
GUCY2D-A52S,GUCY2D,"One publication suggested that this variant possibly causes Leber's congenital amaurosis in a recessive manner, but the frequency data (36% in 1000 genomes) contradicts any significant pathogenic effect.",Low,Uncertain,Benign,0.21,Hearing and vision,Recessive,Homozygous,8944027,rs61749665,,chr17,7906519,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
LOXL1-R141L,LOXL1,"Associated with exfoliative glaucoma & syndrome (XFG & XFS) in various populations, but with contradicting results (protective in Caucasians, pathogenic in Japanese). Based on this it seems the variation itself -- although it affects protein structure -- is not itself causing disease. Instead it is likely associated with other nearby causal variants. As such, it is evaluated as benign by GET-Evidence (which focuses on reporting causal variants). See detailed variant report for disease risk associations.",Low,Uncertain,Benign,0.26,Hearing and vision,Complex/Other,Homozygous,17690259;18450598;20142848,rs1048661,,chr15,74219546,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
TAS2R38-A49P,TAS2R38,"This variant is strongly associated with causing the ""taster"" phenotype of phenylthiocarbamine (PTC) in a dominant manner.",Low,Uncertain,Benign,0.43,Other,Unknown,Heterozygous,12595690;15883422;20675712,rs713598,,chr7,141673345,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
TAS2R38-I296V,TAS2R38,"This variant is associated with ""taster"" status of PTC, along with 49P and 262A. Due to linkage disequilibrium, the independent effects of positions 296 and 262 is unclear. The presence of 49P confers taster status in a dominant fashion, but in the absence of 49P, the presence of 262A/296V is still positively associated with tasting PTC.",Low,Uncertain,Benign,0.46,Other,Unknown,Heterozygous,12595690;20675712,rs10246939,,chr7,141672604,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
BRCA1-Q356R,BRCA1,"One common variant associated this variant with an increased risk of breast cancer, but a more recent, larger study found no association.",Low,Uncertain,Benign,0.046,Cancer,Unknown,Heterozygous,17341484;19661094,rs1799950,,chr17,41246481,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
APOB-Y1422C,APOB,This position is almost certainly an error in the HG18 reference sequence. ,Low,Uncertain,Benign,1.0,Other,Unknown,Homozygous,,rs568413,,chr2,21235475,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
AMPD1-P48L,AMPD1,"Probably benign, ancestral to15173240 pathogenic Q12X mutation.",Low,Uncertain,Benign,0.094,Other,Unknown,Heterozygous,15173240,rs61752479,,chr1,115231254,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
CASP8-M1T,CASP8,"Probably benign. Although start codons can be extremely disruptive and this gene is implicated in a rare disease (autoimmune lymphoproliferative syndrome), the allele frequency for this variant (2-3%) is high enough to contradict such a strong pathogenic effect. This may be because the gene has many other transcripts that do not include this position as exonic.",Low,Uncertain,Benign,0.031,Blood;Immune system,Unknown,Heterozygous,12353035,rs3769824,,chr2,202122956,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
SLC45A2-L374F,SLC45A2,"Pigmentation allele for non-black hair, and consequently, possible increased susceptibility to malignant melanoma.",Low,Uncertain,Benign,0.69,Cancer,Unknown,Homozygous,15714523;17044855;18563784;18806926,rs16891982,,chr5,33951693,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
PCSK9-G670E,PCSK9,This variant is likely benign. ,Low,Uncertain,Benign,0.89,Other,Unknown,Homozygous,19351729,rs505151,,chr1,55529187,A,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
NTRK1-G613V,NTRK1,"Also called G607V, this variant has been reported as a nonpathogenic polymorphism.",Low,Uncertain,Benign,0.043,Other,Unknown,Heterozygous,10330344;10443680;11159935,rs6339,,chr1,156848946,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
NTRK1-H604Y,NTRK1,"Various databases and papers treat this variant as a non-pathogenic polymorphism, although it is fairly uncommon and is computational methods predict it to be damaging.",Low,Uncertain,Benign,0.043,Other,Unknown,Heterozygous,10443680;16412461;21228398,rs6336,,chr1,156848918,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
PKP2-L366P,PKP2,This variant is a benign polymorphism.  ,Low,Uncertain,Benign,0.22,Other,Unknown,Heterozygous,19955750,rs1046116,,chr12,33021934,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
F5-M413T,F5,Presumed benign. This variant is not particularly rare and has not been reported to cause disease.,Low,Uncertain,Benign,0.058,Other,Unknown,Heterozygous,17284699,rs6033,,chr1,169521853,G,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
RP1-N985Y,RP1,"Probably benign. One report linked this variant to high triglycerides, but a later paper found a nearby SNP with similar association and suggests that both findings are caused by linkage to an undiscovered causal variant.",Low,Uncertain,Benign,0.35,Metabolism,Unknown,Heterozygous,12764676;19364639,rs2293869,,chr8,55539395,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
DSP-R1537C,DSP,Probably benign / nonpathogenic.,Low,Uncertain,Benign,0.01,Other,Unknown,Heterozygous,20152563,rs28763967,,chr6,7581032,T,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
F5-D2222G,F5,"Other mutations in this gene are associated with Factor 5 deficiency. There is no literature implicating this variant, however, and it is fairly common in the population (3.8% in HapMap), and so it is currently labeled as benign.",Low,Uncertain,Benign,0.045,Blood,Unknown,Heterozygous,,rs6027,,chr1,169483561,C,http://evidence.pgp-hms.org/genomes?display_genome_id=16574d7d9a6ef3cb30cd9ced971c656bd7e47765&access_token=8fb3c5a8bf21fe7b8fddc3ceedd30ba2
